about
Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescentsUsing N-of-1 trials to improve patient management and save costsTo meta-analyze or not to meta-analyze? A combined meta-analysis of N-of-1 trial data with RCT data on amphetamines and methylphenidate for pediatric ADHD.An n-of-1 trial service in clinical practice: testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder.Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials.Using aggregated single patient (N-of-1) trials to determine the effectiveness of psychostimulants to reduce fatigue in advanced cancer patients: a rationale and protocol.Central nervous system stimulants for secondary attention deficit-hyperactivity disorder after paediatric traumatic brain injury: a rationale and protocol for single patient (n-of-1) multiple cross-over trials.Do pilocarpine drops help dry mouth in palliative care patients: a protocol for an aggregated series of n-of-1 trialsCONSORT extension for reporting N-of-1 trials (CENT) 2015: Explanation and elaboration.CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.The Single-Case Reporting guideline In BEhavioural interventions (SCRIBE) 2016 statement.Melatonin in Youth: N-of-1 trials in a stimulant-treated ADHD Population (MYNAP): study protocol for a randomized controlled trialAggregated n-of-1 trials of central nervous system stimulants versus placebo for paediatric traumatic brain injury--a pilot study.Aggregating single patient (n-of-1) trials in populations where recruitment and retention was difficult: the case of palliative care.N-of-1 trials can be aggregated to generate group mean treatment effects: a systematic review and meta-analysis.Do N-of-1 Trials Need IRB Review?Sun protection policies of Australian primary schools in a region of high sun exposure.Testing pilocarpine drops for dry mouth in advanced cancer using n-of-1 trials: A feasibility study.CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.CONSORT extension for reporting N-of-1 trials (CENT) 2015: explanation and elaboration.A series of N-of-1 trials to assess the therapeutic interchangeability of two enalapril formulations in the treatment of hypertension in Addis Ababa, Ethiopia: study protocol for a randomized controlled trial.Pilot study to determine the optimal dose of methylphenidate for an n-of-1 trial for fatigue in patients with cancer.Exploring melatonin prescribing among customers of compounding pharmacies in Australia.N-of-1 randomized trials to assess the efficacy of gabapentin for chronic neuropathic pain.Are N-of-1 trials an economically viable option to improve access to selected high cost medications? The Australian experience.Management of Whiplash Associated Disorders in Australian general practice.Sun protective behaviors at an outdoor entertainment event in Australia.Pregabalin versus placebo in targeting pro-nociceptive mechanisms to prevent chronic pain after whiplash injury in at-risk individuals - a feasibility study for a randomised controlled trial.A series of n-of-1 trials of stimulants in brain injured children.Valerian does not appear to reduce symptoms for patients with chronic insomnia in general practice using a series of randomised n-of-1 trials.Single-patient multiple crossover studies to determine the effectiveness of paracetamol in relieving pain suffered by patients with advanced cancer taking regular opioids: A pilot study.The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 Statement.The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 Statement.Bias influencing maternal reports of child behaviour and emotional state.Barriers for conducting clinical trials in developing countries- a systematic review.The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 Statement.N-of-1 trials in the clinical care of patients in developing countries: a systematic review.The Effect of Methylphenidate on Fatigue in Advanced Cancer: An Aggregated N-of-1 TrialThe Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 StatementThe Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 Statement
P50
Q24186168-EE976B1F-1ED7-4D0D-8C1D-E2CC768EC8EFQ24594944-C816A324-389B-4E6B-A40B-246361455EEDQ31072289-732B8DAB-E80D-4F62-B7F8-2ABA8DDAC809Q34533047-E3F37371-EB0C-45A7-B400-A2E29D6EB331Q34538663-72E116AB-8378-40CA-B022-6990E1C16762Q34687238-95345068-DA49-4822-A2D5-442873716E28Q34741859-F91EC788-C329-4B22-9A1F-27A126E1706FQ35029512-8302A82E-7E1C-4EB7-B7D7-D30FAB584031Q35632264-770AB03A-0494-4A74-AB18-A85B72AA1F84Q35632331-55D7C62D-0230-4416-8EFE-DA95417C62ACQ36042858-A5AAD62E-8B05-467B-A8A6-14AC825A89A2Q37138835-28FBB7A3-812A-42B3-99B7-1D2BABFAA7DDQ37586413-F7584AE9-7D17-423D-88BD-BA90F8E91C8CQ37798986-1A3ED722-0409-485A-8003-07596B24331CQ38815799-62F84E66-9674-4452-8B0B-38A9D4D34099Q38930102-2CCFB29E-833C-4E1D-921C-9DE9AFD6CD67Q39051132-93A6D4BD-5DDC-4D1F-A961-D8A552573531Q40910978-CC10033B-6DF1-4481-B081-930E04638136Q41483522-8387ECD0-F781-4A0C-A22D-F627AD705990Q41483531-63B49994-52CF-4457-B3B4-4EF57340AF09Q42374169-5706FDCA-471F-45BD-93DD-44697FCBDA31Q42910945-81D7B244-F908-4261-852A-08E4BA48B1FDQ44175376-7D348EAA-48EA-4131-9E8C-A7AC7B30B0F4Q46005410-C02CA43A-C51A-4617-A08D-760ED914C576Q46780600-02BF551E-B0B7-41A2-BCE7-0F44B8D0DAEFQ47122802-E04D50C2-082C-486C-BEC2-81466D474703Q47240540-A95C5ACE-4110-4BAC-83C0-689930514551Q48224476-1E257117-3698-464D-A510-A7F7374CC245Q48439966-BD331803-32B9-4F1A-85A7-7BFE4265A533Q48599089-C3CB3135-9A1D-494C-89AF-66CC7C0EC7AFQ50228176-4581B0D2-AA0B-4019-98F3-D1A4E20077D8Q50897831-F208C0AD-6BD9-47E5-936F-CE81F68D13C2Q50923534-646EAAED-CE6B-44B0-95F7-BDC21D69BCFBQ51063535-DF247E10-FCDB-4B9D-8B66-378F30D9C7ADQ52642376-22E1C00A-872A-4AD6-8606-4FEFEE383519Q53758933-3F206B8A-C215-49AE-A0C5-753AB8249308Q55008394-E65B651C-EA43-4859-9EB0-FAB076CE38EFQ57198091-5D38C491-1742-4723-AD02-8037DE02F41DQ57211200-2B1CF018-D17C-40E2-A4CE-06D6256246E3Q57211219-75046F1A-C2E4-47B6-83C8-681518118EC0
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jane Nikles Nikles
@ast
Jane Nikles Nikles
@en
Jane Nikles Nikles
@es
Jane Nikles Nikles
@nl
Jane Nikles Nikles
@sl
type
label
Jane Nikles Nikles
@ast
Jane Nikles Nikles
@en
Jane Nikles Nikles
@es
Jane Nikles Nikles
@nl
Jane Nikles Nikles
@sl
prefLabel
Jane Nikles Nikles
@ast
Jane Nikles Nikles
@en
Jane Nikles Nikles
@es
Jane Nikles Nikles
@nl
Jane Nikles Nikles
@sl
P106
P1153
6603009156
P21
P31
P496
0000-0001-5356-2291